Vectura Group plc
1 Prospect West
Chippenham
Wiltshire
SN14 6FH
United Kingdom
Tel: 44-0-1249-667700
Fax: 44-0-1249-667701
Website: http://www.vectura.co.uk/
Email: enquiries@vectura.com
139 articles about Vectura Group plc
-
Amidst a chorus of pushback from scientific and health organizations, Philip Morris International’s $1.4 billion offer now has the backing of Vectura Group’s board.
-
Philip Morris will acquire Vectura to gain access to its inhaled drug formulas to bolster its Beyond Nicotine strategy.
-
On Wednesday morning, the company announced that it would be undergoing a $1.36 billion takeover by global investment firm The Carlyle Group.
-
Vectura and Inspira Pharmaceuticals sign Agreement on Development of Potential Inhaled Treatment for COVID-19
5/7/2021
Vectura Group plc, an industry leading inhalation CDMO, and Inspira Pharmaceuticals Limited, a new UK-based company focused on developing therapies for respiratory and infectious diseases, today announced an agreement to develop an inhaled formulation of Inspira’s lead drug candidate for the treatment of COVID-19.
-
Vectura announces the appointment of Sharon Johnson, Executive Vice President for Delivery Management
2/10/2020
Vectura Group plc announces a key appointment to support innovation, customer focus and growth as the company continues with its strategic development as a leading inhalation specialist in the pharmaceutical services space.
-
Pre-close trading update confirms 2019 trading in-line with expectations
1/13/2020
Vectura will report its preliminary results for the year ended 31 December 2019 on Tuesday 17th March 2020.
-
Vectura confirms R&D investment priorities, announces a proposed £50 million capital return and a pre-close trading update
7/17/2019
Vectura Group plc confirms its R&D investment priorities, announces a proposed £50 million capital return and provides an unaudited pre-close trading update.
-
Vectura Wins US GSK Patent Litigation and Awarded $89.7Million in Damages by Trial Jury
5/4/2019
Vectura Group plc confirms that on 3rd May 2019 following a jury trial in the United States District Court for the District of Delaware, the relevant asserted claim of Vectura’s US patent 8303991 was found valid and infringed by US sales of three of GlaxoSmithKline’s Ellipta products.
-
Pre-close trading update confirms good progress against 2018 goals
1/3/2019
Vectura will report its preliminary results for the year ended 31 December 2018 on Tuesday 26 March 2019.
-
Vectura Group plc: Pre-close trading update confirms good progress against 2018 goals
1/3/2019
Vectura Group plc (LSE: VEC) ("Vectura" or "the Group") today announces an unaudited 2018 pre-close trading update. The Group expects revenue to be in line with, and EBITDA to be materially above, current market consensus expectations.
-
Vectura was studying VR475, a drug-device combination consisting of budesonide delivered by Vectura's proprietary nebulizer inhalation system as a treatment for adolescent and adult patients with severe uncontrolled asthma.
-
Vectura Group plc: Interim Results For The Six Months Ended 30 June 2018
9/12/2018
Vectura regaining momentum with continued inhaled revenue and adjusted EBITDA growth
-
It’s been a big year so far for activity in the U.S. biopharma market—record IPOs and plenty of big acquisitions. But things may be heating up in Europe as well.
-
Vectura Group plc Notice of Preliminary Results
2/8/2018
Vectura Group plans to announce its Preliminary Results for the 12 months ended 31 December 2017 on Wednesday 21 March 2018.
-
Vectura Release: Flutiform Breath-Activated K-Haler Makes Positive European Regulatory Progress
10/6/2017
-
Vectura : Mundipharma Presents Positive Findings At ERS 2017
9/12/2017
-
Vectura 2017 Interim Results
9/6/2017
-
Pulmatrix Licenses Inhaled COPD Drug PUR0200 To Vectura
9/6/2017
-
Vectura Release: Hikma Interim Results Statement On Its ANDA For Generic Advair Diskus (VR315)
8/17/2017
-
Vectura Release: Board Change
3/6/2017